228 related articles for article (PubMed ID: 24260544)
1. Chromogranin A and its fragments as regulators of small intestinal neuroendocrine neoplasm proliferation.
Giovinazzo F; Schimmack S; Svejda B; Alaimo D; Pfragner R; Modlin I; Kidd M
PLoS One; 2013; 8(11):e81111. PubMed ID: 24260544
[TBL] [Abstract][Full Text] [Related]
2. Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors.
Svejda B; Kidd M; Timberlake A; Harry K; Kazberouk A; Schimmack S; Lawrence B; Pfragner R; Modlin IM
Cancer Sci; 2013 Jul; 104(7):844-55. PubMed ID: 23578138
[TBL] [Abstract][Full Text] [Related]
3. GNA15 expression in small intestinal neuroendocrine neoplasia: functional and signalling pathway analyses.
Zanini S; Giovinazzo F; Alaimo D; Lawrence B; Pfragner R; Bassi C; Modlin I; Kidd M
Cell Signal; 2015 May; 27(5):899-907. PubMed ID: 25701539
[TBL] [Abstract][Full Text] [Related]
4. Limitations in small intestinal neuroendocrine tumor therapy by mTor kinase inhibition reflect growth factor-mediated PI3K feedback loop activation via ERK1/2 and AKT.
Svejda B; Kidd M; Kazberouk A; Lawrence B; Pfragner R; Modlin IM
Cancer; 2011 Sep; 117(18):4141-54. PubMed ID: 21387274
[TBL] [Abstract][Full Text] [Related]
5. Comparison of PCR-based detection of chromogranin A mRNA with traditional histological lymph node staging of small intestinal neuroendocrine neoplasia.
Lawrence B; Kenney B; Svejda B; Schimmack S; Alaimo D; Barbieri A; Jedrych J; Kidd M; Modlin I
BMC Res Notes; 2012 Jun; 5():318. PubMed ID: 22720672
[TBL] [Abstract][Full Text] [Related]
6. mTOR Pathway in Gastroenteropancreatic Neuroendocrine Tumor (GEP-NETs).
Zanini S; Renzi S; Giovinazzo F; Bermano G
Front Endocrinol (Lausanne); 2020; 11():562505. PubMed ID: 33304317
[TBL] [Abstract][Full Text] [Related]
7. Anti-proliferative and anti-secretory effects of everolimus on human pancreatic neuroendocrine tumors primary cultures: is there any benefit from combination with somatostatin analogs?
Mohamed A; Romano D; Saveanu A; Roche C; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Garcia S; Ferone D; Florio T; Moutardier V; Poizat F; Barlier A; Gerard C
Oncotarget; 2017 Jun; 8(25):41044-41063. PubMed ID: 28454119
[TBL] [Abstract][Full Text] [Related]
8. Combined targeting of AKT and mTOR synergistically inhibits proliferation of hepatocellular carcinoma cells.
Grabinski N; Ewald F; Hofmann BT; Staufer K; Schumacher U; Nashan B; Jücker M
Mol Cancer; 2012 Nov; 11():85. PubMed ID: 23167739
[TBL] [Abstract][Full Text] [Related]
9. Dual inhibition of PI3K and mTOR signaling pathways decreases human pancreatic neuroendocrine tumor metastatic progression.
Djukom C; Porro LJ; Mrazek A; Townsend CM; Hellmich MR; Chao C
Pancreas; 2014 Jan; 43(1):88-92. PubMed ID: 24263107
[TBL] [Abstract][Full Text] [Related]
10. Metastatic pancreatic neuroendocrine tumors have decreased somatostatin expression and increased Akt signaling.
Tran CG; Scott AT; Li G; Sherman SK; Ear PH; Howe JR
Surgery; 2021 Jan; 169(1):155-161. PubMed ID: 32611516
[TBL] [Abstract][Full Text] [Related]
11. Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling.
Xu X; Jiang J; Yao L; Ji B
Med Sci Monit; 2018 Nov; 24():8064-8073. PubMed ID: 30415267
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of mTOR's Catalytic Site by PKI-587 Is a Promising Therapeutic Option for Gastroenteropancreatic Neuroendocrine Tumor Disease.
Freitag H; Christen F; Lewens F; Grass I; Briest F; Iwaszkiewicz S; Siegmund B; Grabowski P
Neuroendocrinology; 2017; 105(1):90-104. PubMed ID: 27513674
[TBL] [Abstract][Full Text] [Related]
13. Everolimus as a new potential antiproliferative agent in aggressive human bronchial carcinoids.
Zatelli MC; Minoia M; Martini C; Tagliati F; Ambrosio MR; Schiavon M; Buratto M; Calabrese F; Gentilin E; Cavallesco G; Berdondini L; Rea F; degli Uberti EC
Endocr Relat Cancer; 2010 Sep; 17(3):719-29. PubMed ID: 20554786
[TBL] [Abstract][Full Text] [Related]
14. The selective PI3Kα inhibitor BYL719 as a novel therapeutic option for neuroendocrine tumors: Results from multiple cell line models.
Nölting S; Rentsch J; Freitag H; Detjen K; Briest F; Möbs M; Weissmann V; Siegmund B; Auernhammer CJ; Aristizabal Prada ET; Lauseker M; Grossman A; Exner S; Fischer C; Grötzinger C; Schrader J; Grabowski P;
PLoS One; 2017; 12(8):e0182852. PubMed ID: 28800359
[TBL] [Abstract][Full Text] [Related]
15. The clinical implications and biologic relevance of neurofilament expression in gastroenteropancreatic neuroendocrine neoplasms.
Schimmack S; Lawrence B; Svejda B; Alaimo D; Schmitz-Winnenthal H; Fischer L; Büchler MW; Kidd M; Modlin I
Cancer; 2012 May; 118(10):2763-75. PubMed ID: 21990041
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of phosphatidylinositol 3-kinase/Akt signaling suppresses tumor cell proliferation and neuroendocrine marker expression in GI carcinoid tumors.
Pitt SC; Chen H; Kunnimalaiyaan M
Ann Surg Oncol; 2009 Oct; 16(10):2936-42. PubMed ID: 19588205
[TBL] [Abstract][Full Text] [Related]
17. Octreotide and the mTOR inhibitor RAD001 (everolimus) block proliferation and interact with the Akt-mTOR-p70S6K pathway in a neuro-endocrine tumour cell Line.
Grozinsky-Glasberg S; Franchi G; Teng M; Leontiou CA; Ribeiro de Oliveira A; Dalino P; Salahuddin N; Korbonits M; Grossman AB
Neuroendocrinology; 2008; 87(3):168-81. PubMed ID: 18025810
[TBL] [Abstract][Full Text] [Related]
18. Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors.
François RA; Maeng K; Nawab A; Kaye FJ; Hochwald SN; Zajac-Kaye M
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971297
[TBL] [Abstract][Full Text] [Related]
19. The biochemical utility of chromogranin A, chromogranin B and cocaine- and amphetamine-regulated transcript for neuroendocrine neoplasia.
Bech PR; Martin NM; Ramachandran R; Bloom SR
Ann Clin Biochem; 2014 Jan; 51(Pt 1):8-21. PubMed ID: 23939195
[TBL] [Abstract][Full Text] [Related]
20. High Sensitivity of Circulating Tumor Cells Derived from a Colorectal Cancer Patient for Dual Inhibition with AKT and mTOR Inhibitors.
Smit DJ; Cayrefourcq L; Haider MT; Hinz N; Pantel K; Alix-Panabières C; Jücker M
Cells; 2020 Sep; 9(9):. PubMed ID: 32962206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
